Drug Search Results
More Filters [+]

Vincristine

Alternative Names: vincristine, vincristina, marqibo, oncovin, Vincristine Sulfate, vincristin, vincasar pfs, vincrex
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

Vincristine is a chemotherapy drug that belongs to a group of drugs called vinca alkaloids. Vincristine works by stopping the cancer cells from separating into 2 new cells. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/vincristine)

Mechanisms of Action: Mitosis Inhibitor,Tubulin Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Acute Leukemia | Acute Lymphoid Leukemia | Leukemia | Lymphoid Leukemia

Known Adverse Events: Insomnia | Anemia | Febrile Neutropenia | Neutropenia | Constipation | Diarrhea

Company: Premier Inc
Company Location:
Company CEO:
Additonal Commercial Interests: Pfizer

Clinical Description

Map of Global Clinical Trials for Vincristine

Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, China, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Korea, Netherlands, Poland, Puerto Rico, Russia, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 9

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|T-Cell Peripheral Lymphoma

Phase 2: Desmoplastic Small Round Cell Tumor|Diffuse Large B-Cell Lymphoma|Osteosarcoma|Peripheral Neuroectodermal Tumors, Primitive|Primitive Neuroectodermal Tumors|Rhabdomyosarcoma|Sarcoma, Ewing|Small Cell Sarcoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CRESCENDO

P3

Recruiting

T-Cell Peripheral Lymphoma

2030-07-01

NCT06709495

P2

Not yet recruiting

Desmoplastic Small Round Cell Tumor|Sarcoma, Ewing|Primitive Neuroectodermal Tumors|Osteosarcoma|Rhabdomyosarcoma|Small Cell Sarcoma|Peripheral Neuroectodermal Tumors, Primitive

2028-11-01

RG1124788

P2

Not yet recruiting

Unknown

2027-12-31

GO43075

P2

Active, not recruiting

Diffuse Large B-Cell Lymphoma

2025-06-01

Recent News Events